288154-17-6

Basic information

• Product Name: tert-butyl 4-(benzyloxycarbonylamino)-4-carbamoylpiperidine-1-carboxylate
• Synonyms: tert-butyl 4-(benzyloxycarbonylamino)-4-carbamoylpiperidine-1-carboxylate
• CAS NO: 288154-17-6
• Molecular Formula: C₁₉H₂₇N₃O₅
• Molecular Weight: 377.43478
• Mol File: 288154-17-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-butyl 4-(benzyloxycarbonylamino)-4-carbamoylpiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(benzyloxycarbonylamino)-4-carbamoylpiperidine-1-carboxylate(288154-17-6)
• EPA Substance Registry System: tert-butyl 4-(benzyloxycarbonylamino)-4-carbamoylpiperidine-1-carboxylate(288154-17-6)

Safety Data

• Hazardous Substances Data: 288154-17-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
Tert-butyl 4-(benzyloxycarbonylamino)-4-carbamoylpiperidine-1-carboxylate serves as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs and biologically active molecules, particularly in the creation of molecules with specific therapeutic targets.
Used in Chemical Synthesis:
In the field of chemical synthesis, tert-butyl 4-(benzyloxycarbonylamino)-4-carbamoylpiperidine-1-carboxylate is utilized as a building block for the assembly of more complex organic molecules. Its functional groups enable it to participate in a range of chemical reactions, facilitating the creation of diverse chemical entities for various applications.
Used in Drug Development:
Tert-butyl 4-(benzyloxycarbonylamino)-4-carbamoylpiperidine-1-carboxylate is employed in drug development as a precursor to potential therapeutic agents. Its specific properties and reactivity make it suitable for the design and synthesis of molecules with desired pharmacological activities, contributing to the advancement of novel treatments for various diseases and conditions.

Upstream product

• 288154-16-5 4-(Benzyloxycarbonylamino)-1-(tert-butoxycarbonyl)-piperidine-4-carboxylic Acid 

Downstream Products

• 180386-33-8 1-(2-phenylethyl)-8-Boc-1,3,8-triazaspiro[4.5]decan-4-one 
• 180386-40-7 1-(2-phenylethyl)-8-Boc-1,3,8-triazaspiro[4.5]decan-4-one-3-acetic acid 
• 288154-21-2 1-(2-phenylethyl)-8-Boc-1,3,8-triazaspiro[4.5]dec-2-en-4-one 
• 288154-19-8 1-Boc-4-[(2-phenylethyl)amino]piperidine-4-carboxamide 
• 288154-18-7 tert-butyl 4-amino-4-carbamoylpiperidine-1-carboxylate 

Relevant articles and documents

ACETYL CoA CARBOXYLASE INHIBITORS

The present invention relates to acetyl coenzyme-A carboxylase (""ACC"") inhibiting compounds of the formula wherein the variables are as defined herein. In particular, the present invention relates to ACC1 and/or ACC2 inhibitors, compositions of matter,

CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: Formula I: I and Formula II: (where variables R1, R2, R3, R4, A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

A rational approach to the design and synthesis of a new bradykinin B1 receptor antagonist

We have previously synthesized a potent and selective B1 bradykinin receptor antagonist, JMV1645 (H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH), containing a dipeptide mimetic ((3S)-amino-5-carbonylmethyl-2,3-dihydro-1,5- benzothiazepin-4(5H)-one (D-B